Multiple-ascending Doses study not checked
Chengdu Zenitar Biomedical Technology Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Obesity With Cardiovascular Risk Study
- Main trialPhase 1
- “This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.”In the company’s words, NCT07946783 on ClinicalTrials.gov
Coming up1
- 30 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07946783
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 30 Sep 2027 | A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026